Clinical Trial Update: Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating gefitinib, AZD9291, or selumetinib plus docetaxel, or an initial immune-mediated therapy with a sequential switch to a second IM…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD9291 (osimertinib)
• DOCETAXEL (DOCETAXEL)
• Gefitinib (Gefitinib)
• MEDI4736 (Durvalumab)
• Selumetinib (selumetinib)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV) | Phase 2 | Status: COMPLETED | Results posted: 2019-08-02